Skip to content

Endoscopic Full Thickness Resection in the Lower GI Tract With the Full Thickness Resection Device

Endoscopic Full Thickness Resection in the Lower GI Tract With the Full Thickness Resection Device- A Prospective Multicenter Trial

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02362126
Acronym
WALL-RESECT
Enrollment
80
Registered
2015-02-12
Start date
2015-02-28
Completion date
2017-02-28
Last updated
2015-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Adenomas, Submucosal Tumors

Keywords

Endoscopic full thickness resection, EFTR, FTRD, OTSC

Brief summary

Observational prospective multicenter study to investigate efficacy and safety of endoscopic full thickness resection in the lower GI tract using a novel over-the-scope full thickness resection device.

Detailed description

The FTRD (Full Thickness Resection Device, Ovesco Endoscopy, Tübingen, Germany) is an over the scope device consisting of a transparent cap with a preloaded monofilament snare and and a 14 mm modified Over-the-scope Clip. The device is CE marked for full thickness resection in the lower GI tract. The study was designed to investigate efficacy and safety of this device for full thickness resection of colorectal lesions.

Interventions

DEVICEEndoscopic full thickness resection (EFTR)

Patients undergo EFTR using the FTRD

Sponsors

Ovesco Endoscopy AG
CollaboratorINDUSTRY
Kliniken Ludwigsburg-Bietigheim gGmbH
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 y * Adenoma with negtive lifting sign * Adenoma involving or next to a diverticulum * Adenoma involving or next to the appendical orifice * T1 carcinoma with indication for endoscopic (re-)resection * Subepithelial colorectal tumor with indication for resection

Exclusion criteria

* Lesions \>3 cm * T1 carcinomas with known high-risk features (submucosal infiltration\>1000 um, invasion of lymphatic vessels, poor differentiation (G3)) * Lesions in the upper GI tract * Patients with colorectal stenosis * Patinets not able to undergo informed consent * Pregnancy * Patients with urgent indication for dual thrombocyte aggregation inhibition

Design outcomes

Primary

MeasureTime frameDescription
Technical successImmediateSuccessful enbloc- and macroscopically complete resection
R0-Resection3 daysHistologically confirmed complete resection

Secondary

MeasureTime frameDescription
Procedure timeimmediateProcedure time
Histologically confirmed full thickness resection3 daysHistologically confirmed full thickness resection
Residual or recurrent adenoma/carcinoma at endoscopic follow up3 months
Necessity of surgical treatment3 months
Procedure-associated complications3 monthsProcedure-associated complications such as bleeding or perforation

Countries

Germany

Contacts

Primary ContactArthur R Schmidt, MD
arthur.schmidt@kliniken-lb.de0049 (0) 7141 99 67201
Backup ContactKarel Caca, MD, PhD
karel.caca@kliniken-lb.de0049 (0) 7141 99 67201

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026